Vaccine Preventable Disease
12
1
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
42%
5 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Impact of Catch-up HPV Vaccination
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Measles and BCG Vaccines for Mother and Child
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
COVID-19 Antibody Levels After Vaccines
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
Study of Gam-COVID-Vac in Adolescents
Iron and Vaccine Response
Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations
COVID-19 Vaccine For Indirect Protection